Horizon Therapeutics Sustainability Profile
Horizon Therapeutics plc, commonly referred to as Horizon, is a biopharmaceutical company headquartered in the United States, with significant operations across North America and Europe. Founded in 2008, Horizon focuses on developing innovative medicines for rare and rheumatic diseases, positioning itself as a leader in the industry. The company’s core products, including Tepezza and Krystexxa, are distinguished by their targeted approaches to treatment, addressing unmet medical needs in conditions such as thyroid eye disease and chronic gout. Horizon's commitment to research and development has led to notable achievements, including rapid growth and recognition within the biopharmaceutical sector. With a strong market presence, Horizon Therapeutics continues to advance its mission of improving patient outcomes through innovative therapies.
DitchCarbon Score
How does Horizon Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Horizon Therapeutics's score of 8 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Horizon Therapeutics's reported carbon emissions
Horizon Therapeutics, headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it report specific reduction targets or initiatives. The absence of emissions data suggests that the company may still be in the early stages of formalising its climate commitments. As of now, there are no specific climate pledges or targets outlined by Horizon Therapeutics, indicating a potential area for development in their sustainability strategy. Without inherited emissions data from a parent company or established reduction initiatives, it remains unclear how Horizon Therapeutics plans to address its carbon footprint or contribute to broader climate goals. In the context of the pharmaceutical industry, companies are increasingly expected to adopt transparent climate strategies and set science-based targets to mitigate their environmental impact. Horizon Therapeutics may benefit from aligning with industry standards and best practices to enhance its climate commitments in the future.
How Carbon Intensive is Horizon Therapeutics's Industry?
How Carbon Intensive is Horizon Therapeutics's Location?
Horizon Therapeutics's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Horizon Therapeutics has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
